Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Festival holidays wind down, the production line at Nanyang Yaoyibao Mugwort Products Company (hereafter as Yaoyibao Company) in Nanyang, Central China's Henan Province, roars back to life. The air ...

Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...

H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).

Recognizing Siegel’s importance as an employee and a respected figure among Israeli psychiatrists, Lundbeck Global took ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Denmark has two annual holidays that differ from many other countries. One is “efterårsferie” (Autumn break) which is always ...

Yesterday, four of Denmark’s largest companies released their financial reports: Demant, Lundbeck, Pandora, and Vestas. All ...

Lundbeck’s total revenue grew by +14% at constant exchange rates (CER) and 11% in kroner terms to 22,004 million kroner ...